Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Cost-Effectiveness of Rivaroxaban versus Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation in the Guangdong Healthcare Setting in China

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: ZHOU, Jing (guangzhou, China)
  • Co-author(s): Jing Zhou: Department of Pharmacy, Guangdong General Hospital (Guangdong Academy of Medical Sciences), Guangzhou, China
    Biyu Huang: Department of Pharmacy, Guangdong General Hospital (Guangdong Academy of Medical Sciences), Guangzhou, China
    Min Yang: Department of Pharmacy, Guangdong General Hospital (Guangdong Academy of Medical Sciences), Guangzhou, China
  • Abstract:

    Backgrounds

    Warfarin has been the mainstay of anticoagulant therapy for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). Rivaroxaban, a novel oral anticoagulant which offers some distinct advantages over warfarin has been introduced.

    Aims

    To evaluate the cost-effectiveness of rivaroxaban versus warfarin for stroke prevention

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses